MEDRX CO., LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131 JPY | +4.80% |
|
+10.08% | -13.25% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,699 | 4,139 | 3,949 | 3,148 | 2,665 | 5,793 |
| Enterprise Value (EV) 1 | 3,903 | 2,729 | 2,187 | 1,445 | 1,671 | 4,073 |
| P/E ratio | -4.4 x | -2.26 x | -3.08 x | -2.58 x | -2.17 x | -5.63 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 712 x | 24.5 x | 34.3 x | 394 x | 45.2 x | 200 x |
| EV / Revenue | 488 x | 16.1 x | 19 x | 181 x | 28.3 x | 140 x |
| EV / EBITDA | -3.16 x | -1.72 x | -2.1 x | -1.44 x | -1.58 x | -4.58 x |
| EV / FCF | -5.15 x | -2.21 x | -3.14 x | -2.73 x | -2.56 x | -7.15 x |
| FCF Yield | -19.4% | -45.2% | -31.8% | -36.7% | -39% | -14% |
| Price to Book | 2.67 x | 2.17 x | 1.91 x | 1.61 x | 2.21 x | 3.01 x |
| Nbr of stocks (in thousands) | 10,214 | 13,614 | 18,715 | 24,595 | 28,054 | 38,365 |
| Reference price 2 | 558.0 | 304.0 | 211.0 | 128.0 | 95.00 | 151.0 |
| Announcement Date | 3/27/19 | 3/30/20 | 3/29/21 | 3/31/22 | 3/28/23 | 3/29/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8 | 169 | 115 | 8 | 59 | 29 |
| EBITDA 1 | -1,234 | -1,588 | -1,041 | -1,001 | -1,055 | -889 |
| EBIT 1 | -1,273 | -1,628 | -1,096 | -1,061 | -1,101 | -934 |
| Operating Margin | -15,912.5% | -963.31% | -953.04% | -13,262.5% | -1,866.1% | -3,220.69% |
| Earnings before Tax (EBT) 1 | -1,265 | -1,612 | -1,106 | -1,058 | -1,110 | -930 |
| Net income 1 | -1,267 | -1,616 | -1,114 | -1,059 | -1,111 | -932 |
| Net margin | -15,837.5% | -956.21% | -968.7% | -13,237.5% | -1,883.05% | -3,213.79% |
| EPS 2 | -126.7 | -134.3 | -68.57 | -49.58 | -43.80 | -26.80 |
| Free Cash Flow 1 | -758.6 | -1,234 | -696 | -529.8 | -652.1 | -569.8 |
| FCF margin | -9,482.81% | -729.88% | -605.22% | -6,621.88% | -1,105.3% | -1,964.66% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/19 | 3/30/20 | 3/29/21 | 3/31/22 | 3/28/23 | 3/29/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 15 | 7 | 1 | 1 | 9 | - | 6 | 6 | 23 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -706 | -471 | -204 | -189 | -374 | -247 | -294 | -478 | -192 | -176 |
| Operating Margin | -4,706.67% | -6,728.57% | -20,400% | -18,900% | -4,155.56% | - | -4,900% | -7,966.67% | -834.78% | - |
| Earnings before Tax (EBT) 1 | -707 | -471 | -204 | -196 | -380 | -253 | -289 | -480 | -188 | -127 |
| Net income 1 | -713 | -473 | -204 | -196 | -381 | -254 | -290 | -481 | -190 | -128 |
| Net margin | -4,753.33% | -6,757.14% | -20,400% | -19,600% | -4,233.33% | - | -4,833.33% | -8,016.67% | -826.09% | - |
| EPS 2 | -47.11 | -23.94 | -8.990 | -8.010 | -15.50 | -10.32 | -9.610 | -14.97 | -5.030 | -3.330 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/6/20 | 8/10/21 | 11/12/21 | 5/13/22 | 8/10/22 | 11/11/22 | 5/12/23 | 8/10/23 | 11/10/23 | 5/10/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,796 | 1,410 | 1,762 | 1,703 | 994 | 1,720 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -759 | -1,234 | -696 | -530 | -652 | -570 |
| ROE (net income / shareholders' equity) | -60.8% | -79.8% | -54.8% | -51.6% | -70.2% | -59.5% |
| ROA (Net income/ Total Assets) | -35.8% | -46.7% | -31.5% | -30.1% | -39.3% | -33.8% |
| Assets 1 | 3,538 | 3,461 | 3,532 | 3,517 | 2,830 | 2,754 |
| Book Value Per Share 2 | 209.0 | 140.0 | 110.0 | 79.50 | 42.90 | 50.10 |
| Cash Flow per Share 2 | 176.0 | 103.0 | 93.20 | 69.20 | 35.20 | 44.80 |
| Capex 1 | 42 | 252 | 39 | 2 | 1 | - |
| Capex / Sales | 525% | 149.11% | 33.91% | 25% | 1.69% | - |
| Announcement Date | 3/27/19 | 3/30/20 | 3/29/21 | 3/31/22 | 3/28/23 | 3/29/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.25% | 32.96M | |
| +14.12% | 74.45B | |
| +11.35% | 9.18B | |
| +60.16% | 5.03B | |
| -12.85% | 5.02B | |
| +1.60% | 3.82B | |
| -19.20% | 2.41B | |
| +19.16% | 2.39B | |
| -27.46% | 2.27B | |
| +24.62% | 2.26B |
- Stock Market
- Equities
- 4586 Stock
- Financials MedRx Co., Ltd